|
|
|
|
EMPIRIC COMBINATION ANTIBIOTIC THERAPY IS ASSOCIATED WITH IMPROVED OUTCOME IN GRAM-NEGATIVE SEPSIS: A RETROSPECTIVE ANALYSIS [Article]
EMPIRIC COMBINATION ANTIBIOTIC THERAPY IS ASSOCIATED WITH IMPROVED OUTCOME IN GRAM-NEGATIVE SEPSIS: A RETROSPECTIVE ANALYSIS Scott T.Micek, Emily C. Welch, Junaid Khan, Mubashir Pervez, Joshua A. Doherty, Richard M. Reichley, and Marin H. Kollef*...
|
|
|
Procalcitonin levels Predict Bacteremia in Patients with community-acquired Pneumonia: A prospective cohort trial.
Fabian Mller , MD1, Mirjam Christ-Crain , MD1, Thomas Bregenzer , MD2, Martin Krause , MD3, Werner Zimmerli , MD4, Beat Mueller , MD2,* and Philipp Schuetz , MD1 for the ProHOSP Study Group* 1Department of Internal Medicine, Division of Endocrinology, Diabetes...
|
|
|
Bacteremia complicating gram-negative urinary tract infections: A population-based study
_ Bacteremia complicating gram-negative urinary tract infections: A population-based study.
|
|
|
The epidemiology of recurrent Gram-negative bacteremia in a tertiary-care hospital
were reviewed for microbial etiology and susceptibilities.Patient charts were reviewed to determine the source of infection and outcome. Results Forty-five nosocomial Gram-negative bacteremias occurred in 44 patients. Infection rates of 6.9/1000...
|
|
|
Comparison of the clinical and microbiologic characteristics of patients with Enterobacter cloacae and Enterob
Eun Hee Songa, c, Ki-Ho Parka, c, Eun-Young Janga, c, Eun Jung Leea, c, Yong Pil Chonga, c, Oh-Hyun Choa, c, Sung-Han Kima, c, Sang-Oh Leea, c, Heungsup Sungb, Mi-Na Kimb, Jin-Yong Jeonga, c, Yang Soo Kima, c, Jun Hee Wooa, c and Sang-Ho Choia, c, , a...
|
|
|
Erratum to Resolution of persistent Pediococcus bacteremia with daptomycin treatment: case report and review o
_ Erratum to Resolution of persistent Pediococcus bacteremia with daptomycin treatment: case report and review o.
|
|
|
Reactive erythema secondary to adult T-cell leukemia and Helicobacter cinaedi bacteremia
_ Reactive erythema secondary to adult T-cell leukemia and Helicobacter cinaedi bacteremia.
|
|
|
Gram-negative bacteremia induces greater magnitude of inflammatory response than Gram-positive bacteremia
Abe R et al.The incidence of Gramnegative bacteremia was significantly higher in bacteremic ICU patients with septic shock than in those with sepsis or severe sepsis. Furthermore, CRP and IL6 levels were significantly higher in Gramnegative ...
|
|
|
A Randomized Double-Blind Controlled Trial of Taurolidine-Citrate Catheter Locks for the Prevention of Bacteremia in Patients Treated With Hemodialysis
Solomon LR et al.Taurolidinecitrate use did not decrease allcause bacteremia and was associated with a greater need for thrombolytic treatment. A Randomized Double-Blind Controlled Trial of Taurolidine-Citrate Catheter Locks for the Prevention of ...
|
|
|
MicroPhage Seeks FDA Clearance To Market World's First Test Designed To Rapidly Identify Bacterial Infections
MicroPhage announced that it has submitted human data from a pivotal clinical study of its 'Microphage MRSA/MSSA Blood Culture Test' to support a U.S.Food and Drug Administration (FDA) 510(k) premarket notification process. The first of MicroPhage's...
|
|
|
MicroPhage Seeks FDA Clearance To Market World's First Test Designed To Rapidly Identify Bacterial Infections
MicroPhage announced that it has submitted human data from a pivotal clinical study of its 'Microphage MRSA/MSSA Blood Culture Test' to support a U.S.Food and Drug Administration (FDA) 510(k) premarket notification process. The first of MicroPhage's...
|
|
|
Medical News: Innovative HeRO(R) Device Improves Outcomes, Quality Of Life For Kidney Disease Patients
One thousand end stage renal disease patients have now benefited from a novel device that provides vital access to their blood for filtering and replacement kidney function, and reduces the risk of potentially fatal bacteremia infection.The HeRO...
|
|
|
Innovative HeRO(R) Device Improves Outcomes, Quality Of Life For Kidney Disease Patients
One thousand end stage renal disease patients have now benefited from a novel device that provides vital access to their blood for filtering and replacement kidney function, and reduces the risk of potentially fatal bacteremia infection.The HeRO...
|
|
|
Innovative HeRO(R) Device Improves Outcomes, Quality Of Life For Kidney Disease Patients
One thousand end stage renal disease patients have now benefited from a novel device that provides vital access to their blood for filtering and replacement kidney function, and reduces the risk of potentially fatal bacteremia infection.The HeRO...
|
|
|
Pfizer Receives FDA Approval for Prevnar 13„ for the Prevention of Invasive Pneumococcal Disease in In
Let the jobs come to you!Pfizer Inc! (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted approval for Prevnar 13? (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company?s 13-valent...
|
|
|
Paenibacillus larvae Bacteremia in Injection Drug Users
_ Paenibacillus larvae Bacteremia in Injection Drug Users.
|
|
|
Pfizer Receives FDA Approval For Prevnar 13
Pfizer has received an approval from the US Food and Drug Administration (FDA) for Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the companys 13-valent pneumococcal conjugate vaccine.According to the company, Prevnar 13...
|
|
|
Innovative HeRO Device Improves Outcomes, Quality of Life for Kidney Disease Patients
1,000 patients nationwide have now received the device from Minnesota-based Hemosphere, Inc.EDEN PRAIRIE, Minn.(BUSINESS WIRE) One thousand end stage renal disease patients have now benefited from a novel device that provides vital access to their blood for...
|
|
|
Innovative HeRO Device Improves Outcomes, Quality of Life for Kidney Disease Patients
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--One thousand end stage renal disease patients have now benefited from a novel device that provides vital access to their blood for filtering and replacement kidney function, and reduces the risk of potentially fatal ...
|
|
|
Pfizer Receives FDA Approval For Prevnar 13 For The Prevention Of Invasive Pneumococcal Disease In Infants And Young Children
Pfizer Inc.(NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted approval for Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company's 13-valent pneumococcal conjugate vaccine...
|
|
|
GlycoVaxyns First Clinical Study with Bioconjugate Vaccine Initiated
te Safety, Reactogenicity and Immunogenicity of Vaccine Against Shigella dysenteriae25 Feb 2010 - GlycoVaxyn has commenced a Phase I clinical study with its vaccine candidate (GVXN SD133) against Shigella dysenteriae, a cause of serious intestinal infections.
|
|
|
Pfizer Receives FDA Approval for Prevnar 13? for the Prevention of Invasive Pneumococcal Disease in Infants an
NEW YORK(BUSINESS WIRE) Pfizer Inc.(NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted approval for Prevnar 13? (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company's 13-valent...
|
|
|
Pfizer Receives FDA Approval for Prevnar 13 for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children
NEW YORK(BUSINESS WIRE) Pfizer Inc.(NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted approval for Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Companys 13-valent...
|
|
|
FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine
Pfizer Inc.(NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted approval for Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Companys 13-valent pneumococcal conjugate vaccine....
|
|
|
Drug stocks advance; PharmAthene retreats
Drug stocks climbed Wednesday while shares of PharmAthene Inc.retreated after jumping in the previous session on news the company was awarded additional government funding for its anthrax vaccine SparVax. The NYSE Arca Pharmaceutical Index edged up 0.6% to...
|
